Management of Aluminum Phosphide Poisoning in ICU

Respiratory Management

• The American Society of Anesthesiologists recommends considering continuous positive airway pressure (CPAP) ventilation for patients with adequate consciousness and without contraindications 1
• High-flux dialysis membranes may be beneficial if available, according to the American Journal of Kidney Diseases 2

Management of Multi-organ Failure

• The American Society of Anesthesiologists suggests watching for and treating rhabdomyolysis with adequate hydration and urine alkalinization if myoglobinuria develops 1
• Monitoring serum creatinine kinase and potassium can help detect rhabdomyolysis, as recommended by the American Society of Anesthesiologists 1

Special Considerations

• The American Journal of Kidney Diseases recommends measuring serum aluminum levels if aluminum toxicity is suspected, particularly in dialysis patients 3
• For confirmed aluminum toxicity with levels >60μg/L but <200μg/L, the American Journal of Kidney Diseases suggests administering deferoxamine (DFO) at 5 mg/kg 3, 4
• The American Journal of Kidney Diseases advises against administering DFO if serum aluminum levels are >200μg/L due to risk of neurotoxicity, and instead recommends intensive dialysis 3

Management of Aluminum Phosphide Poisoning

Patient Care

• Avoid physical restraints without adequate sedation as this can worsen outcomes 5
• Phosphine gas released from AlP is highly toxic and can affect healthcare providers; ensure proper ventilation of treatment areas 6

Management of Aluminum Phosphide Poisoning

Cardiovascular and Metabolic Support

• The American Journal of Kidney Diseases recommends treating hyperkalemia with calcium gluconate for cardiac membrane stabilization in life-threatening arrhythmias 7
• The American Journal of Kidney Diseases suggests that deferoxamine (DFO) should not be administered if serum aluminum levels are >200μg/L due to risk of neurotoxicity; instead, perform intensive dialysis with high-flux membranes 8
• The American Journal of Kidney Diseases advises against administering intravenous iron to limit formation of feroxamine if DFO is administered 8
• High-flux dialysis membranes are recommended for more effective clearance of aluminum-DFO complexes by the American Journal of Kidney Diseases 9 and 8
• Aluminum hydroxide should be limited to 1-2 days when used as a phosphate binder to avoid cumulative aluminum toxicity, as suggested by the Journal of Clinical Oncology 7
• DFO therapy can precipitate fatal mucormycosis; reduced dosing (5 mg/kg) and expanded intervals between treatments are recommended to minimize risk by the American Journal of Kidney Diseases 8

Management of Aluminum Phosphide Poisoning

Metabolic and Renal Support

• Administration of sodium bicarbonate (1-2 mEq/kg IV push) can be considered for severe acidosis, as recommended by the American College of Medical Toxicology 10
• Do not use aluminum hydroxide as a phosphate binder for more than 1-2 days to avoid cumulative aluminum toxicity, as suggested by the National Kidney Foundation 10
• Do not administer sodium bicarbonate and calcium through the same IV line, as advised by the American Heart Association 10

Critical Pitfalls to Avoid

• Ingestion of as little as 150-500 mg can be fatal, and all exposures require ICU-level care, according to the American Association of Poison Control Centers 10
• Calcium gluconate (100-200 mg/kg/dose) via slow infusion with ECG monitoring can be given for life-threatening arrhythmias, as recommended by the American College of Cardiology 10

Aluminum Phosphide Poisoning: Critical Care Considerations

Special Considerations for Aluminum Toxicity

• For serum aluminum levels >200 μg/L, the American Journal of Kidney Diseases recommends against administering Deferoxamine (DFO) due to the high risk of precipitating acute aluminum neurotoxicity, and instead suggests intensive dialysis with high-flux membranes (daily hemodialysis for 4-6 weeks until levels decrease) 11, 12
• The American Journal of Kidney Diseases advises that for serum aluminum levels between 60-200 μg/L, DFO should be administered at 5 mg/kg with careful monitoring, and high-flux dialysis membranes should be used for more effective clearance of aluminum-DFO complexes 11
• Fatal mucormycosis can occur with DFO therapy, with a mortality rate of 91% in dialysis patients, according to the American Journal of Kidney Diseases, and reduced dosing (5 mg/kg) and expanded intervals between treatments can help minimize this risk 12, 13

Management of Aluminum Phosphide Poisoning

Cardiovascular Support

• The American Heart Association recommends avoiding the use of succinylcholine or mivacurium for intubation if cholinesterase inhibition is suspected, as stated by the Circulation journal 14

Management of Aluminum Phosphide (Phostoxin) Poisoning – Evidence‑Based Interventions

Gastrointestinal Decontamination

• Activated charcoal can be considered for gastrointestinal decontamination in patients with aluminum phosphide ingestion, although its ability to adsorb phosphine gas is uncertain (low‑quality evidence) 15.

Management of Elevated Serum Aluminum Levels

• In patients with serum aluminum concentrations > 200 µg/L, deferoxamine should be withheld because it may precipitate acute neurotoxicity; instead, intensive high‑flux hemodialysis (daily for 4–6 weeks until levels fall) is recommended (moderate‑quality evidence) 16.

Healthcare Worker Safety in Aluminum Phosphide Exposure

Environmental Controls

• Ensure treatment areas are well‑ventilated; in poorly ventilated spaces healthcare workers required atropine, pralidoxime, and intubation after exposure to phosphine vapor. 17

Personal Protective Equipment

• Never initiate patient care without full‑face gas masks and butyl rubber gloves; secondary exposure has caused severe illness requiring ICU admission in healthcare workers. 17

Deferoxamine Use in Aluminum Phosphide (Sulphos) Poisoning

Indications Based on Serum Aluminum Concentration

• When serum aluminum concentrations are between 60 µg/L and 200 µg/L, administer deferoxamine (DFO) at 5 mg/kg intravenously with careful monitoring; use high‑flux dialysis membranes to enhance clearance of aluminum‑DFO complexes. This recommendation is derived from data reported in the American Journal of Kidney Diseases (2003) and reflects expert consensus rather than a formal guideline, so the strength of evidence is not explicitly graded. 18

• When serum aluminum concentrations exceed 200 µg/L, deferoxamine should be avoided because of a high risk of precipitating acute aluminum neurotoxicity; instead, initiate intensive high‑flux hemodialysis daily for 4–6 weeks until levels decline. This approach is also based on the same 2003 American Journal of Kidney Diseases publication, with evidence strength not formally classified. 18